Esperion Therapeutics - Ann Arbor Revenue and Competitors

Claim your profile

Detroit, MI USA

Location

$764.2M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Esperion Therapeutics - Ann Arbor's estimated annual revenue is currently $73.1M per year.(i)
  • Esperion Therapeutics - Ann Arbor received $151.9M in venture funding in August 2017.
  • Esperion Therapeutics - Ann Arbor's estimated revenue per employee is $251,250
  • Esperion Therapeutics - Ann Arbor's total funding is $764.2M.

Employee Data

  • Esperion Therapeutics - Ann Arbor has 291 Employees.(i)
  • Esperion Therapeutics - Ann Arbor grew their employee count by -35% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$58.8M23410%$10.8MN/A
#2
$7M350%N/AN/A
#3
$5.5M6752%N/AN/A
#4
$16.1M9718%N/AN/A
#5
$44.2M2208%N/AN/A
#6
$73.1M291-35%$764.2MN/A
#7
$2.7M33-15%N/AN/A
#8
$5.6M28-15%N/AN/A
#9
$3.8M1990%N/AN/A
#10
$4.3M5224%N/AN/A

Esperion is the Lipid Management Company passionately committed to developing and commercializing convenient, complementary, consistent, once-daily, oral therapies for the treatment of patients with elevated LDL-C. Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering therapies that will make a substantial impact on reducing global cardiovascular disease; the leading cause of death around the world. The Company has two late-stage therapies in development; both with confirmed regulatory pathways to approval and defined global pivotal Phase 3 clinical development plans. Bempedoic acid and the Company's lead product candidate, the bempedoic acid / ezetimibe combination pill, are targeted therapies that have been shown to significantly reduce elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies. Phase 1 and 2 studies conducted previously in more than 800 patients treated with bempedoic acid have produced clinically relevant LDL-C lowering results of up to 30 percent as monotherapy, approximately 50 percent in combination with ezetimibe, 64% when added-on to atorvastatin 20 mg, and an incremental 20+ percent when added to stable statin therapy. The Company has two Phase 3 products in development: 1) the once-daily, oral fixed dose bempedoic acid / ezetimibe combination pill, and 2) bempedoic acid (monotherapy) a once-daily, oral pill. For more information, please visit www.esperion.com.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$764.2M

Total Funding

291

Number of Employees

$73.1M

Revenue (est)

-35%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Esperion Therapeutics - Ann Arbor News

2022-04-17 - Esperion to Report First Quarter 2022 Financial Results May 3, 2022 Yahoo Finance

Esperion to Report First Quarter 2022 Financial Results May 3, 2022 Yahoo Finance

2022-03-30 - Esperion to Participate in Upcoming 21st Annual Needham Virtual ... GlobeNewswire

Esperion to Participate in Upcoming 21st Annual Needham Virtual ... GlobeNewswire

2022-03-30 - Esperion Announces Two NEXLETOL® (bempedoic acid) Data ... GlobeNewswire

Esperion Announces Two NEXLETOL® (bempedoic acid) Data ... GlobeNewswire

2021-10-25 - Esperion Therapeutics : Announces Agreement to Exchange $15 Million in Principal Amount of its 4.00% Convertible Senior Subordinated Notes due 2025 for Common Stock

ANN ARBOR, Mich., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a privately negotiated exchange agreement with two co-managed holders (the “Holders”) of its 4.00% Convertible Senior Subordinated Notes due 2025 (the "Notes"). Under the terms of ...

2021-10-25 - Esperion Therapeutics : Announces Agreement to Exchange $15 Million in Principal Amount of its 4.00% Convertible Senior Subordinated Notes due 2025 for Common Stock - Form 8-K

ESPERION Announces Agreement to Exchange $15 Million in Principal Amount of its 4.00% Convertible Senior Subordinated Notes due 2025 for Common Stock ANN ARBOR, Mich., October 25, 2021 (GLOBE NEWSWIRE) - Esperion (NASDAQ: ESPR) today announced that it has entered into a privately negotiated exc ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$57.8M292-1%N/A
#2
$101.9M30214%N/A
#3
$53.2M304-3%N/A
#4
$55.1M304-1%N/A
#5
$750M304N/AN/A

Esperion Therapeutics - Ann Arbor Funding

DateAmountRoundLead InvestorsReference
2003-08-01$64.0MPublic OfferingArticle
2013-04-26$33.0MUndisclosedLongitude CapitalArticle
2015-03-19$172.5MUndisclosedCredit Suisse Securities (USA)Article
2017-08-11$151.9MUndisclosedMultipleArticle